Search results
Added:
1 year ago
In this Meet the Experts session, from e-SPACE Heart Failure 2024, Prof Andrew Coats and Dr Patricia Campbell engage in an in-depth discussion on SGLT2 inhibitors, focusing on their real-world application in clinical practice.
View more
Added:
1 year ago
HFSA 24 - We are joined virtually by Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss findings from the STEP-HFpEF trial programme in regard to the efficacy of semaglutide according to frailty status, and exercise function at baseline.Interview Questions:1. Could you remind us of the importance of STEP-HFpEF2. What was the study design and patient population?3. What…
View more
Added:
2 months ago
ACC.26 – Dr Navin Kapur (Tufts Medicine, Boston, MA, US) joins us to discuss findings from the STEMI-Door To Unload (DTU) randomised clinical trial, examining whether primary left ventricular unloading with the Impella CP® device prior to reperfusion can reduce infarct size and heart failure-related outcomes in patients presenting with anterior ST-elevation myocardial infarction.This prospective,…
View more
Added:
5 months ago
Explore the diagnostic and therapeutic complexities of cardiac sarcoidosis with Prof Emer Joyce.This presentation, part of the comprehensive Cardiomyopathies track, tackles the persistent challenges in cardiac sarcoidosis, emphasizing that despite decades of clinical experience, diagnosis remains the field's greatest hurdle.Prof Joyce explores the heterogeneous clinical phenotypes capable of…
View more
Added:
9 months ago
ESC Congress 2025 - REBOOT-MI finds that beta-blocker therapy after MI did not reduce the occurrence of adverse events in patients with LVEF greater than 40%.Dr Borja Ibanez (National Centre for Cardiovascular Research, Madrid, ES) joins us to discuss findings from REBOOT-CNIC (NCT03596385). The prospective, randomised, open-label trial investigated the benefits of long-term betablocker therapy…
View more
Added:
1 month ago
ACC 26 - Dr Paul Sorajja (Banner Health in Phoenix, Arizona, US) and Prof Lars Sondergaard (Chief Medical Officer and Divisional Vice President, Medical Affairs, Abbott) discuss the role of TriClip TEER in treating patients with severe tricuspid regurgitation and new data showcasing how TriClip TEER provides significant reduction in heart failure hospitalization relative to medical therapy…
View more
Added:
6 months ago
AHA Scientific Sessions 2025 - Dr Milton Packer (Baylor University Medical Center, US) joins us to discuss his novel unifying hypothesis that heart failure with preserved ejection fraction arises primarily from visceral adipose tissue dysfunction and altered adipokine signaling, rather than as a heterogeneous disorder driven by multiple comorbidities.Interview Questions:Can you explain the core…
View more
Added:
1 year ago
In this Meet the Experts session, from e-SPACE Heart Failure 2024, Prof Marianna Fontana and Prof Arnt Kristen explore the management of transthyretin amyloid cardiomyopathy (ATTRCM) and discuss strategies for optimising patient care pathways.
View more
Added:
1 year ago
AHA Conference 2024 — REALIZE-K: Impact of sodium zirconium cyclosilicate (SZC) on HFrEF patient's potassium levels whilst on spironolactone.Late-Breaker Host, Dr Harriette Van Spall (McMaster University, CA) is joined onsite by Dr Mikhail Kosiborod (Saint Luke's Mid America Heart Institute, US) to discuss the findings from the REALIZE-K Study (NCT04676646; AstraZeneca).REALIZE-K is a phase 4…
View more
Added:
2 years ago
HFA 2024 — Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) sat down with Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss insights from the STEP-HFpEF programme.STEP HFpEF aimed to test the hypothesis that treatment with semaglutide can improve symptoms in patients with HFpEF and obesity. This discussion centers around the background of the…
View more